Works by Sakai, Soichi

Results: 25

Pharmacokinetics and Pharmacodynamics of Luseogliflozin, a Selective SGLT2 Inhibitor, in Japanese Patients With Type 2 Diabetes With Mild to Severe Renal Impairment.

Published in:

Clinical Pharmacology in Drug Development, 2018, v. 7, n. 8, p. 820, doi. 10.1002/cpdd.456

By:

Samukawa, Yoshishige;
Haneda, Masakazu;
Seino, Yutaka;
Sasaki, Takashi;
Fukatsu, Atsushi;
Kubo, Yusuke;
Sato, Yuri;
Sakai, Soichi

Publication type:

Article

Luseogliflozin, an SGLT2 Inhibitor, in Japanese Patients With Mild/Moderate Hepatic Impairment: A Pharmacokinetic Study.

Published in:

Clinical Pharmacology in Drug Development, 2017, v. 6, n. 5, p. 439, doi. 10.1002/cpdd.364

By:

Samukawa, Yoshishige;
Sata, Michio;
Furihata, Kenichi;
Ito, Toshifumi;
Ueda, Naohiko;
Ochiai, Hidekazu;
Sakai, Soichi;
Kumagai, Yuji

Publication type:

Article

Efficacy and Safety of Lipase Inhibitor Orlistat in Japanese with Excessive Visceral Fat Accumulation: 24-Week, Double-Blind, Randomized, Placebo-Controlled Study.

Published in:

2019

By:

Shirai, Kohji;
Fujita, Toru;
Tanaka, Michitaka;
Fujii, Yuka;
Shimomasuda, Masatsugu;
Sakai, Soichi;
Samukawa, Yoshishige

Publication type:

journal article

Reduction of Excessive Visceral Fat and Safety with 52-Week Administration of Lipase Inhibitor Orlistat in Japanese: Long-Term Clinical Study.

Published in:

Advances in Therapy, 2019, v. 36, n. 1, p. 217, doi. 10.1007/s12325-018-0822-x

By:

Shirai, Kohji;
Tanaka, Michitaka;
Fujita, Toru;
Fujii, Yuka;
Shimomasuda, Masatsugu;
Sakai, Soichi;
Samukawa, Yoshishige

Publication type:

Article

Reduction of Excessive Visceral Fat and Safety with 52-Week Administration of Lipase Inhibitor Orlistat in Japanese: Long-Term Clinical Study.

Published in:

2018

By:

Shirai, Kohji;
Tanaka, Michitaka;
Fujita, Toru;
Fujii, Yuka;
Shimomasuda, Masatsugu;
Sakai, Soichi;
Samukawa, Yoshishige

Publication type:

journal article

Substantial Effects of Luseogliflozin Revealed by Analyzing Responses to Postprandial Hyperglycemia: Post Hoc Subanalyses of a Randomized Controlled Study.

Published in:

2016

By:

Samukawa, Yoshishige;
Omiya, Hirohisa;
Watase, Hirotaka;
Nozaki, Kazunari;
Sakai, Soichi;
Nishimura, Rimei

Publication type:

journal article

Impact of Reduced Renal Function on the Glucose-Lowering Effects of Luseogliflozin, a Selective SGLT2 Inhibitor, Assessed by Continuous Glucose Monitoring in Japanese Patients with Type 2 Diabetes Mellitus.

Published in:

2016

By:

Jinnouchi, Hideaki;
Nozaki, Kazunari;
Watase, Hirotaka;
Omiya, Hirohisa;
Sakai, Soichi;
Samukawa, Yoshishige

Publication type:

journal article

Absence of Drug-Drug Interactions Between Luseogliflozin, a Sodium-Glucose Co-transporter-2 Inhibitor, and Various Oral Antidiabetic Drugs in Healthy Japanese Males.

Published in:

Advances in Therapy, 2015, v. 32, n. 5, p. 404, doi. 10.1007/s12325-015-0209-1

By:

Sasaki, Takashi;
Seino, Yutaka;
Fukatsu, Atsushi;
Ubukata, Michito;
Sakai, Soichi;
Samukawa, Yoshishige

Publication type:

Article

Pharmacokinetics, Pharmacodynamics, and Safety of Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Single-blind, Placebo-controlled Trial.

Published in:

Advances in Therapy, 2015, v. 32, n. 4, p. 319, doi. 10.1007/s12325-015-0200-x

By:

Sasaki, Takashi;
Seino, Yutaka;
Fukatsu, Atsushi;
Ubukata, Michito;
Sakai, Soichi;
Samukawa, Yoshishige

Publication type:

Article

Safety, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Luseogliflozin Dosing in Healthy Japanese Males: A Randomized, Single-Blind, Placebo-Controlled Trial.

Published in:

Advances in Therapy, 2014, v. 31, n. 3, p. 345, doi. 10.1007/s12325-014-0102-3

By:

Sasaki, Takashi;
Seino, Yutaka;
Fukatsu, Atsushi;
Sakai, Soichi;
Samukawa, Yoshishige

Publication type:

Article

Sodium‐glucose cotransporter‐2 inhibitor luseogliflozin added to glucagon‐like peptide 1 receptor agonist liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: A 52‐week, open‐label, single‐arm study

Published in:

Journal of Diabetes Investigation, 2018, v. 9, n. 2, p. 332, doi. 10.1111/jdi.12694

By:

Seino, Yutaka;
Yabe, Daisuke;
Sasaki, Takashi;
Fukatsu, Atsushi;
Imazeki, Hisae;
Ochiai, Hidekazu;
Sakai, Soichi

Publication type:

Article

Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus.

Published in:

Journal of Diabetes Investigation, 2015, v. 6, n. 4, p. 443, doi. 10.1111/jdi.12316

By:

Seino, Yutaka;
Inagaki, Nobuya;
Haneda, Masakazu;
Kaku, Kohei;
Sasaki, Takashi;
Fukatsu, Atsushi;
Ubukata, Michito;
Sakai, Soichi;
Samukawa, Yoshishige

Publication type:

Article

Favorable therapeutic efficacy of low‐density lipoprotein apheresis for nephrotic syndrome with impaired renal function.

Published in:

Therapeutic Apheresis & Dialysis, 2022, v. 26, n. 1, p. 220, doi. 10.1111/1744-9987.13694

By:

Muso, Eri;
Sakai, Soichi;
Ogura, Youske;
Yukawa, Susumu;
Nishizawa, Yoshiki;
Yorioka, Noriaki;
Saito, Takao;
Mune, Masatoshi;
Sugiyama, Satoshi;
Iino, Yasuhiko;
Hirano, Tsutomu;
Hattori, Motoshi;
Watanabe, Tsuyoshi;
Yokoyama, Hitoshi;
Sato, Hiroshi;
Uchida, Shunya;
Wada, Takashi;
Shoji, Tetsuo;
Oda, Hiroaki;
Mori, Kiyoshi

Publication type:

Article

Immediate therapeutic efficacy of low-density lipoprotein apheresis for drug-resistant nephrotic syndrome: evidence from the short-term results from the POLARIS Study.

Published in:

Clinical & Experimental Nephrology, 2015, v. 19, n. 3, p. 379, doi. 10.1007/s10157-014-0996-8

By:

Muso, Eri;
Mune, Masatoshi;
Hirano, Tsutomu;
Hattori, Motoshi;
Kimura, Kenjiro;
Watanabe, Tsuyoshi;
Yokoyama, Hitoshi;
Sato, Hiroshi;
Uchida, Shunya;
Wada, Takashi;
Shoji, Tetsuo;
Yuzawa, Yukio;
Takemura, Tsukasa;
Sugiyama, Satoshi;
Nishizawa, Yoshiki;
Ogahara, Satoru;
Yorioka, Noriaki;
Sakai, Soichi;
Ogura, Yosuke;
Yukawa, Susumu

Publication type:

Article

SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria.

Published in:

Biopharmaceutics & Drug Disposition, 2014, v. 35, n. 7, p. 391, doi. 10.1002/bdd.1909

By:

Chino, Yukihiro;
Samukawa, Yoshishige;
Sakai, Soichi;
Nakai, Yasuhiro;
Yamaguchi, Jun‐ichi;
Nakanishi, Takeo;
Tamai, Ikumi

Publication type:

Article

Fifty-two-week long-term clinical study of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.

Published in:

Endocrine Journal, 2015, v. 62, n. 7, p. 593, doi. 10.1507/endocrj.ej15-0097

By:

Yutaka Seino;
Kohei Kaku;
Nobuya Inagaki;
Masakazu Haneda;
Takashi Sasaki;
Atsushi Fukatsu;
Michito Ubukata;
Soichi Sakai;
Yoshishige Samukawa

Publication type:

Article

Role of hepatic lipase in intermediate-density lipoprotein and small, dense low-density lipoprotein formation in hemodialysis patients.

Published in:

Kidney International, 1999, v. 56, p. S227, doi. 10.1046/j.1523-1755.1999.07159.x

By:

Oi, Keiko;
Hirano, Tsutomu;
Sakai, Soichi;
Kawaguchi, Yoshindo;
Hosoya, Tatsuo

Publication type:

Article

Role of hepatic lipase in intermediate-density lipoprotein and small, dense low-density lipoprotein formation in hemodialysis patients.

Published in:

Kidney International Supplement, 1999, n. 71, p. S-227

By:

Oi, Keiko;
Hirano, Tsutomu;
Sakai, Soichi;
Kawaguchi, Yoshindo;
Hosoya, Tatsuo

Publication type:

Article

Efficacy and safety of luseogliflozin added to insulin therapy in Japanese patients with type 2 diabetes: a multicenter, 52-week, clinical study with a 16-week, double-blind period and a 36-week, open-label period.

Published in:

2018

By:

Seino, Yutaka;
Sasaki, Takashi;
Fukatsu, Atsushi;
Imazeki, Hisae;
Ochiai, Hidekazu;
Sakai, Soichi

Publication type:

journal article

Corrigendum.

Published in:

2015

By:

Seino, Yutaka;
Sasaki, Takashi;
Fukatsu, Atsushi;
Ubukata, Michito;
Sakai, Soichi;
Samukawa, Yoshishige

Publication type:

Correction Notice

Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study.

Published in:

Current Medical Research & Opinion, 2014, v. 30, n. 7, p. 1219, doi. 10.1185/03007995.2014.901943

By:

Seino, Yutaka;
Sasaki, Takashi;
Fukatsu, Atsushi;
Sakai, Soichi;
Samukawa, Yoshishige

Publication type:

Article

Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study.

Published in:

Current Medical Research & Opinion, 2014, v. 30, n. 7, p. 1231, doi. 10.1185/03007995.2014.909390

By:

Seino, Yutaka;
Sasaki, Takashi;
Fukatsu, Atsushi;
Ubukata, Michito;
Sakai, Soichi;
Samukawa, Yoshishige

Publication type:

Article

Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study.

Published in:

Current Medical Research & Opinion, 2014, v. 30, n. 7, p. 1245, doi. 10.1185/03007995.2014.912983

By:

Seino, Yutaka;
Sasaki, Takashi;
Fukatsu, Atsushi;
Ubukata, Michito;
Sakai, Soichi;
Samukawa, Yoshishige

Publication type:

Article

Randomized, Controlled, Thorough QT/QTc Study Shows Absence of QT Prolongation with Luseogliflozin in Healthy Japanese Subjects.

Published in:

PLoS ONE, 2015, v. 10, n. 10, p. 1, doi. 10.1371/journal.pone.0139873

By:

Kumagai, Yuji;
Hasunuma, Tomoko;
Sakai, Soichi;
Ochiai, Hidekazu;
Samukawa, Yoshishige

Publication type:

Article

Metabolite profiling and enzyme reaction phenotyping of luseogliflozin, a sodium–glucose cotransporter 2 inhibitor, in humans.

Published in:

Xenobiotica, 2017, v. 47, n. 4, p. 332, doi. 10.1080/00498254.2016.1193263

By:

Miyata, Atsunori;
Hasegawa, Masatoshi;
Hachiuma, Kenji;
Mori, Haruyuki;
Horiuchi, Nobuko;
Mizuno-Yasuhira, Akiko;
Chino, Yukihiro;
Jingu, Shigeji;
Sakai, Soichi;
Samukawa, Yoshishige;
Nakai, Yasuhiro;
Yamaguchi, Jun-ichi

Publication type:

Article